Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov-Dec;29(8):1287-94.
doi: 10.1016/j.jdiacomp.2015.07.013. Epub 2015 Jul 17.

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

Mamta Jaiswal  1 , Catherine L Martin  2 , Morton B Brown  3 , Brian Callaghan  1 , James W Albers  1 , Eva L Feldman  1 , Rodica Pop-Busui  4
Affiliations
Randomized Controlled Trial

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

Mamta Jaiswal et al. J Diabetes Complications. 2015 Nov-Dec.

Abstract

Objective: Experimental studies have reported potential benefit of glucagon-like peptide-1(GLP-1) receptor agonists in preventing diabetic peripheral neuropathy (DPN). We therefore performed a proof-of-concept pilot study to evaluate the effect of exenatide, a GLP-1 agonist, on measures of DPN and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes (T2D).

Research design and methods: Forty-six T2D subjects (age 54±10years, diabetes duration 8±5years, HbA1c 8.2±1.3%) with mild to moderate DPN at baseline were randomized to receive either twice daily exenatide (n=22) or daily insulin glargine (n=24). The subjects, with similar HbA1c levels, were followed for 18months. The primary end point was the prevalence of confirmed clinical neuropathy (CCN). Changes in measures of CAN, other measures of small fiber neuropathy such as intra-epidermal nerve fiber density (IENFD), and quality of life were also analyzed.

Results: Glucose control was similar in both groups during the study. There were no statistically significant treatment group differences in the prevalence of CCN, IENFD, measures of CAN, nerve conductions studies, or quality of life indices.

Conclusions: In this pilot study of patients with T2D and mild to moderate DPN, 18months of exenatide treatment had no significant effect on measures of neuropathy compared with glargine treatment.

Trial registration: ClinicalTrials.gov NCT00855439.

Keywords: Cardiovascular autonomic neuropathy; Clinical trial; Diabetic peripheral neuropathy; Exenatide; GLP-1receptor agonist; Glargine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Changes in the HbA1c levels from baseline to end of study in the exenatide (blue line) and glargine (red line) groups
Figure 3
Figure 3
Changes in intraepidermal nerve fiber density in the exenatide (blue line) and glargine (red line) groups
See this image and copyright information in PMC

References

    1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–2293. - PMC - PubMed
    1. DCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med. 1993;329:977–986. - PubMed
    1. DCCT: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995;38:869–880. - PubMed
    1. DCCT: The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia. 1998;41:416–423. - PMC - PubMed
    1. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14:528. - PMC - PubMed

Publication types

MeSH terms

Associated data